These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
657 related items for PubMed ID: 15389811
21. Endocrine therapy for prostate cancer. Labrie F. Endocrinol Metab Clin North Am; 1991 Dec; 20(4):845-72. PubMed ID: 1778180 [Abstract] [Full Text] [Related]
27. Endocrine therapy: where do we stand and where are we going? Schröder FH. Cancer Surv; 1991 Feb; 11():177-94. PubMed ID: 1841751 [Abstract] [Full Text] [Related]
28. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group. J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218 [Abstract] [Full Text] [Related]
29. The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence. Ginzburg S, Albertsen PC. Endocrinol Metab Clin North Am; 2011 Sep; 40(3):615-23, ix. PubMed ID: 21889724 [Abstract] [Full Text] [Related]
30. Mechanisms of prostate cancer progression to androgen independence. McPhaul MJ. Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793 [Abstract] [Full Text] [Related]
31. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation. Nelson EC, Cambio AJ, Yang JC, Lara PN, Evans CP. Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869 [Abstract] [Full Text] [Related]
33. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378 [Abstract] [Full Text] [Related]
34. Advanced prostatic carcinoma. Early versus late endocrine therapy. Kozlowski JM, Ellis WJ, Grayhack JT. Urol Clin North Am; 1991 Feb; 18(1):15-24. PubMed ID: 1992569 [Abstract] [Full Text] [Related]
35. Complete androgen blockade for the treatment of prostate cancer. Labrie F, Dupont A, Belanger A. Important Adv Oncol; 1985 Feb; ():193-217. PubMed ID: 3916740 [No Abstract] [Full Text] [Related]
36. The androgen receptor for the radiation oncologist. Quero L, Rozet F, Beuzeboc P, Hennequin C. Cancer Radiother; 2015 May; 19(3):220-7. PubMed ID: 25921704 [Abstract] [Full Text] [Related]
37. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate. Middleman MN, Lush RM, Figg WD. Pharmacotherapy; 1996 May; 16(3):376-81. PubMed ID: 8726595 [Abstract] [Full Text] [Related]